In a second multicenter, observational study in Japan, for the 47 patients 75 years or older who received first-line pembrolizumab monotherapy for advanced NSCLC, median OS was NR (95% CI: 10.3â€“NR).28 Other previous retrospective studies of patients with advanced NSCLC treated with ICI therapy in Japan differed in patient population or study design, thus precluding comparisons with our findings.29, 30, 31